Perrigo Eyes $115 Bil. Worth Of Rx-To-OTC Switches On The Horizon
This article was originally published in The Tan Sheet
Executive Summary
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
You may also be interested in...
Sales & Earnings In Brief
Prestige Brands rolls out FiberChoice, BC Powder brand extensions; subsidiary cross-selling aids Atrium Innovations; Dr. Reddy’s downplays switch outlook; Nu Skin gears up for ageLOC weight management launch; more Sales & Earnings In Brief.
Sales & Earnings In Brief
Prestige Brands rolls out FiberChoice, BC Powder brand extensions; subsidiary cross-selling aids Atrium Innovations; Dr. Reddy’s downplays switch outlook; Nu Skin gears up for ageLOC weight management launch; more Sales & Earnings In Brief.
Perrigo Sets Strategy For Global Infant Formula Growth
The private labeler’s more than 60 planned product launches include Codex-compliant infant formulas. The firm also sees marketing formula in plastic containers as a U.S. sales driver.